J.W. Cole Advisors, Inc. Heron Therapeutics, Inc. Transaction History
J.W. Cole Advisors, Inc.
- $3.14 Billion
- Q1 2025
A detailed history of J.W. Cole Advisors, Inc. transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, J.W. Cole Advisors, Inc. holds 16,000 shares of HRTX stock, worth $33,280. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,000
Previous 15,000
6.67%
Holding current value
$33,280
Previous $22,000
59.09%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding HRTX
# of Institutions
182Shares Held
125MCall Options Held
847KPut Options Held
47.7K-
Rubric Capital Management LP New York, NY26.7MShares$55.6 Million1.68% of portfolio
-
Black Rock Inc. New York, NY8.33MShares$17.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.23MShares$17.1 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA7.85MShares$16.3 Million0.03% of portfolio
-
Velan Capital Investment Management LP Alpharetta, GA6.99MShares$14.5 Million26.51% of portfolio
About HERON THERAPEUTICS, INC.
- Ticker HRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 118,774,000
- Market Cap $247M
- Description
- Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...